116 related articles for article (PubMed ID: 38842325)
1. Determining tissue distribution of the oral antileishmanial agent miltefosine: a physiologically-based pharmacokinetic modeling approach.
Ramisetty BS; Yang S; Dorlo TPC; Wang MZ
Antimicrob Agents Chemother; 2024 Jul; 68(7):e0032824. PubMed ID: 38842325
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
Peters SA
Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
[TBL] [Abstract][Full Text] [Related]
3. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
Peters SA
Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
[TBL] [Abstract][Full Text] [Related]
4. A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans.
Bi Y; Deng J; Murry DJ; An G
AAPS J; 2016 Jan; 18(1):228-38. PubMed ID: 26559435
[TBL] [Abstract][Full Text] [Related]
5. A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.
Hu ZY; Lu J; Zhao Y
Br J Pharmacol; 2014 Jun; 171(11):2778-89. PubMed ID: 24471734
[TBL] [Abstract][Full Text] [Related]
6. Assessing Dose-Exposure-Response Relationships of Miltefosine in Adults and Children using Physiologically-Based Pharmacokinetic Modeling Approach.
Madu SJ; Wang K; Chirumamilla SK; Turner DB; Steel PG; Li M
Pharm Res; 2023 Dec; 40(12):2983-3000. PubMed ID: 37816929
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.
Scotcher D; Melillo N; Tadimalla S; Darwich AS; Ziemian S; Ogungbenro K; Schütz G; Sourbron S; Galetin A
Mol Pharm; 2021 Aug; 18(8):2997-3009. PubMed ID: 34283621
[TBL] [Abstract][Full Text] [Related]
8. Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human.
Wu N; An G
AAPS J; 2020 Sep; 22(6):125. PubMed ID: 32996028
[TBL] [Abstract][Full Text] [Related]
9. A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition.
Dubbelboer IR; Lilienberg E; Sjögren E; Lennernäs H
Mol Pharm; 2017 Mar; 14(3):686-698. PubMed ID: 28182434
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125.
Kawai R; Lemaire M; Steimer JL; Bruelisauer A; Niederberger W; Rowland M
J Pharmacokinet Biopharm; 1994 Oct; 22(5):327-65. PubMed ID: 7791036
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based pharmacokinetic models of 2',3'-dideoxyinosine.
Kang HJ; Wientjes MG; Au JL
Pharm Res; 1997 Mar; 14(3):337-44. PubMed ID: 9098877
[TBL] [Abstract][Full Text] [Related]
12. Development and Verification of a Linked
Patilea-Vrana GI; Unadkat JD
Drug Metab Dispos; 2021 Jul; 49(7):509-520. PubMed ID: 33952608
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modelling and simulation to predict the plasma concentration profile of schaftoside after oral administration of total flavonoids of
Li X; Chen C; Ding N; Zhang T; Zheng P; Yang M
Front Pharmacol; 2022; 13():1073535. PubMed ID: 36588682
[No Abstract] [Full Text] [Related]
14. Successful Prediction of Human Pharmacokinetics by Improving Calculation Processes of Physiologically Based Pharmacokinetic Approach.
Mayumi K; Ohnishi S; Hasegawa H
J Pharm Sci; 2019 Aug; 108(8):2718-2727. PubMed ID: 30876861
[TBL] [Abstract][Full Text] [Related]
15. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
Poulin P; Theil FP
J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
[TBL] [Abstract][Full Text] [Related]
16. Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice.
Sharma A; Li M; Thavathiru E; Ibrahim M; Garcia-Contreras L; Benbrook DM; Woo S
AAPS J; 2020 Feb; 22(2):51. PubMed ID: 32086622
[TBL] [Abstract][Full Text] [Related]
17. Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data.
Kagan L; Gershkovich P; Wasan KM; Mager DE
AAPS J; 2011 Jun; 13(2):255-64. PubMed ID: 21431453
[TBL] [Abstract][Full Text] [Related]
18. Risk assessment for humans using physiologically based pharmacokinetic model of diethyl phthalate and its major metabolite, monoethyl phthalate.
Jeong SH; Jang JH; Cho HY; Lee YB
Arch Toxicol; 2020 Jul; 94(7):2377-2400. PubMed ID: 32303804
[TBL] [Abstract][Full Text] [Related]
19. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization.
Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L
Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287
[TBL] [Abstract][Full Text] [Related]
20. Utility of Minimal Physiologically Based Pharmacokinetic Models for Assessing Fractional Distribution, Oral Absorption, and Series-Compartment Models of Hepatic Clearance.
Li X; Jusko WJ
Drug Metab Dispos; 2023 Oct; 51(10):1403-1418. PubMed ID: 37460222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
